READUS-PV:药品安全信号检测中比例失衡分析的报告规范解读
READUS-PV声明旨在促进基于个例安全报告的比例失衡分析研究的透明与全面报告,以解决此类研究缺乏特定指南、报告不完整和结论易误读的问题。本文详细解释了最终保留的14个条目,阐述其原理并提供实践要点,以推动作者、编辑、审稿人和读者采纳该规范。
要点
- READUS-PV指南包含14个条目,用于规范比例失衡分析的报告。
- 该指南旨在提高报告透明度、完整性和准确性,促进正确解读结果。
- 推动作者、编辑、审稿人和读者采纳该指南,以支持循证决策。
核心结论
- READUS-PV指南通过14个条目促进比例失衡分析的透明和全面报告,最终支持药物警戒中的循证决策。
研究设计与样本
- 本文为READUS-PV声明的解释与阐述文件,呈现最终保留的14个条目并深入解释其原理和实践要点。
主要发现
- 比例失衡分析的报告缺乏特定指南,常导致不完整和模糊的报告,且数据未置于正确背景时存在错误结论的风险。
关键数值与推荐
- READUS-PV指南保留了14个条目,每个条目附有原理说明和实践要点。
临床怎么用
- 作者、编辑、审稿人和读者应采纳READUS-PV指南,以提高比例失衡分析报告的透明度、完整性和准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In pharmacovigilance, disproportionality analyses based on individual case safety reports are widely used to detect safety signals. Unfortunately, publishing disproportionality analyses lacks specific guidelines, often leading to incomplete and ambiguous reporting, and carries the risk of incorrect conclusions when data are not placed in the correct context. The REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV) statement was developed to address this issue by promoting transparent and comprehensive reporting of disproportionality studies. While the statement paper explains in greater detail the procedure followed to develop these guidelines, with this explanation paper we present the 14 items retained for READUS-PV guidelines, together with an in-depth explanation of their rationale and bullet points to illustrate their practical implementation. Our primary objective is to foster the adoption of the READUS-PV guidelines among authors, editors, peer reviewers, and readers of disproportionality analyses. Enhancing transparency, completeness, and accuracy of reporting, as well as proper interpretation of their results, READUS-PV guidelines will ultimately facilitate evidence-based decision making in pharmacovigilance.
引用
- Fusaroli M, Salvo F, Begaud B, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf. 2024. PMID: 38713347. doi:10.1007/s40264-024-01423-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。